- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Daly Explains the Importance of Updating Pathways With New Data
As new breakthrough therapies are approved, clinical pathways have to be kept updated in order for patients to get the best treatments, said Robert Daly, MD, MBA, medical oncologist, Memorial Sloan Kettering Cancer Center.
As new breakthrough therapies are approved, clinical pathways have to be kept updated in order for patients to get the best treatments, said Robert Daly, MD, MBA, medical oncologist, Memorial Sloan Kettering Cancer Center.
Transcript
How does the latest evidence get introduced into pathways in a way that is seamless and not disruptive to the clinicians providing care?
I think that there are, at this time in oncology, so many breakthroughs as far as new drugs being approved, that really can have a significant impact on a patient’s course of care. And, so, I think for pathway vendors, so vendors that are not home grown, so they weren’t developed by the institution, but they’re an outside vendor, I think the responsibility really is on them to have frequent meetings where those pathways are addressed, have the ability to have ad hoc sessions where pathways are modified based on breakthroughs in the data or based on these clinical conferences, and I think they have to be very transparent about who’s on these committees so that patients and other physicians really understand who is making the decisions about these pathways and that there’s expert input. Because we really rely on those experts to help sort through and sift these data and make decisions about what are the best treatments for patients and where they should be on the pathway.
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD
June 22nd 2025Delivering value-based cancer care requires overcoming hurdles to access care and tailoring care that prioritizes the quality-of-life metrics the patient values, explained Coral Omene, MD, PhD.
Read More
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More
